KRYS Quote, Financials, Valuation and Earnings

Aldeyra Therapeutics, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of --. Krystal Biotech, Inc.'s return on equity of 19.91% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Krystal Biotech, Inc. has a consensus price target of $217.70, signalling upside risk potential of 2.55%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 98.09%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Krystal Biotech, Inc.'s net income of $79.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 32.62x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 17.39x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of 20.1%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Krystal Biotech, Inc. has a consensus price target of $217.70, signalling upside risk potential of 2.55%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 5.77%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Krystal Biotech, Inc.'s net income of $79.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 32.62x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,934.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 17.39x versus 19.09x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of -259.95%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Insmed, Inc.'s return on equity of -193.23%.

Krystal Biotech, Inc. has a consensus price target of $217.70, signalling upside risk potential of 2.55%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Insmed, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Insmed, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Insmed, Inc.'s net income of -$370M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 32.62x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 17.39x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 81.15% compared to Krystal Biotech, Inc.'s net margin of -40.15%. Krystal Biotech, Inc.'s return on equity of 19.91% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Krystal Biotech, Inc. has a consensus price target of $217.70, signalling upside risk potential of 2.55%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.485, which suggesting that the stock is 51.528% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $97.8M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Krystal Biotech, Inc.'s net income of $79.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 32.62x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 17.39x versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.